Marc Wilson serves as the Chief Financial Officer at Crinetics Pharmaceuticals Inc., a biopharmaceutical company focused on developing novel therapeutics for rare endocrine diseases and endocrine-related tumors. In his role, Wilson is responsible for overseeing the financial operations and strategy of the company, ensuring its fiscal health and supporting its growth trajectory. His leadership has been instrumental in guiding Crinetics through various stages of development, from early-stage research to clinical trials and beyond. Wilson brings a wealth of experience to Crinetics, having spent over two decades in the life sciences industry. Prior to joining Crinetics, he held significant financial leadership positions at several notable biotech firms, including Arena Pharmaceuticals and Amylin Pharmaceuticals. At Arena, he played a key role in the company's financial strategy, which culminated in the successful launch of the obesity drug Belviq. His tenure at Amylin saw him contribute to the company's growth and eventual acquisition by Bristol-Myers Squibb. Wilson's extensive background in financial planning, capital raising, and strategic partnerships has been a critical asset to Crinetics as it advances its mission to bring innovative treatments to patients with unmet medical needs. In addition to his professional achievements, Wilson is known for his strategic foresight and ability to navigate complex financial landscapes. His contributions at Crinetics have not only bolstered the company's financial stability but have also supported its efforts in advancing its pipeline of potential therapies. Under his guidance, Crinetics has successfully raised significant capital through public and private financings, enabling the company to progress its clinical programs and expand its research capabilities. Wilson's dedication to the company's vision and his expertise in the biotech sector continue to drive Crinetics forward as it seeks to make a meaningful impact in the field of endocrinology.